CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0648 (clinicaltrials.gov NCT No: NCT02115295)
Title:PHASE II STUDY OF CLADRIBINE PLUS IDARUBICIN PLUS CYTARABINE (ARAC) IN PATIENTS WITH AML, HR MDS, OR MYELOID BLAST PHASE OF CML
Principal Investigator:Tapan Kadia
Treatment Agent:Cladribine; Cytarabine; Idarubicin
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
cladribine, idarubicin, and cytarabine can help to control AML, high risk MDS,
and/or CML in blast phase. The safety of these drugs will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Cladribine
Cytarabine
Idarubicin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Tapan Kadia
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults